ABCG2 and cancer: On the other hand, several TKIs have also been shown to inhibit the function of ABC-transporters, thereby interfering with drug efflux from cancer cells and providing an attractive therapeutic option to overcome MDR-related resistance to the conventional chemotherapeutic agents.